BIOS Option Care Health Inc

BioScrip Appoints Richard Denness as Chief Commercial Officer

BioScrip Appoints Richard Denness as Chief Commercial Officer

DENVER, July 10, 2018 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced the appointment of Richard Denness as Senior Vice President, Chief Commercial Officer of the Company, effective July 9, 2018.

Mr. Denness brings 29 years of healthcare experience to BioScrip, including two decades in executive leadership roles.  Key positions held by Mr. Denness include General Manager, Australia/New Zealand at Schering-Plough, President at IVAX Laboratories (now Teva Respiratory), Vice President and General Manager, Neurology at UCB, CEO of Vycor Medical, and Managing Director at Proudfoot Consulting.  Most recently, he held the position of Managing Director and Global Healthcare Lead at North Highland Consulting.  His vast experience in leading teams to achieve record results includes growing UCB’s epilepsy franchise nearly five-fold, into a global market leader, while establishing the biopharmaceutical company’s first blockbuster medication exceeding $1 billion in annual revenue.  Mr. Denness possesses highly-relevant commercial experience in sales, marketing, and managed care, complemented by a deep strategic background.

“On behalf of our Board of Directors and management team, I am thrilled to welcome Rich to BioScrip,” said Daniel E. Greenleaf, President and Chief Executive Officer. “He brings us extensive healthcare experience, is results driven, and has a proven track record of driving profitable growth and achieving targeted metrics, while providing visionary and collaborative leadership, throughout his career.  Rich’s appointment rounds out our best-in-class senior management team, positioning us well to capture the enormous potential of BioScrip and the home infusion marketplace.”

Mr. Denness commented, “I am very excited to join BioScrip at this pivotal time in its transformation and look forward to working closely with senior leadership to drive profitable growth and value-creation for all stakeholders.  BioScrip’s independent national platform and dedicated workforce, which is singularly focused on providing the highest standard of care to infusion therapy patients in the home setting, underpin my confidence in the Company’s future.”  

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Contacts:

Stephen Deitsch

Chief Financial Officer & Treasurer 

T:  (720) 697-5200

Kalle Ahl, CFA

The Equity Group

T:  (212) 836-9614

  

EN
10/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Option Care Health Inc

 PRESS RELEASE

Option Care Health to Announce Third Quarter 2019 Financial Results an...

Option Care Health to Announce Third Quarter 2019 Financial Results and Host Conference Call BANNOCKBURN, Ill., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Option Care Health Inc. (NASDAQ: BIOS), the nation’s largest independent national provider of home and alternate site infusion services, today announced that the Company will release results for its third quarter ended September 30, 2019 on Wednesday, November 6, 2019 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call Details ...

 PRESS RELEASE

BioScrip Announces Shareholder Approval of Merger with Option Care

BioScrip Announces Shareholder Approval of Merger with Option Care DENVER, Aug. 02, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the “Company”), the largest independent national provider of infusion and home care management solutions, today announced that its stockholders approved the proposals that are conditions to the proposed merger with Option Care at the Company’s special meeting of stockholders held earlier today.  BioScrip’s merger with Option Care is expected to close on or about August 6, 2019. About BioScrip, Inc. BioScrip, Inc. is the largest ...

 PRESS RELEASE

BioScrip Reports Second Quarter 2019 Financial Results

BioScrip Reports Second Quarter 2019 Financial Results DENVER, July 30, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2019 financial results. Second Quarter 2019 BioScrip Highlights Net revenue of $191.5 million, up 8.9% compared to $175.8 million in the second quarter of 2018.Gross revenue1 of $196.8 million, up 13.1% compared to $174.0 million in the prior year quarter.Net loss from continuing operations of $14.2 million, ...

 PRESS RELEASE

Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Recomme...

Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend that BioScrip Stockholders Vote “FOR” the Transaction Proposals in Connection with the Proposed Merger with Option Care DENVER, July 22, 2019 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip"), the largest independent national provider of infusion and home care management solutions, today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), leading independent proxy advisory firms, recommend that BioScrip stockholders vote “FOR” the proposals that are cond...

Increased risk weighs on BIOSCRIP INCO., penalising its rating down t...

The independent financial analyst theScreener just lowered the general evaluation of BIOSCRIP INCO. (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 3 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 14, 2019, the clos...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch